The Industry Standard: Intelligence for the Information Economy

  September 5, 2001
  NEWS & ANALYSIS
   Headlines
   Money & Markets
   Tech & Telecom
   Media & Marketing
   Metrics & Stats
   Policy & Politics
  SEARCH
   
  advanced search
  SERVICES
   Company Index
   Newsletters
   Wireless
  PRINT EDITION
   Read the Magazine

Home > Company Index > Drugs > Biotechnology-Research > Athersys, Inc.

Athersys, Inc.
 PROFILE
Biotechnology is all the RAGE at Athersys. The development-stage company uses its Random Activation of Gene Expression (RAGE) technology to scan the human genome, identify proteins with specific biological functions, and link those protein functions with gene structures (functional genomics). The firm plans to leverage its RAGE-built protein expression libraries by partnering with other biotechs and drugmakers, but it ultimately wants to count itself among them, developing its own proprietary drugs. Its SMC (Synthetic Microchromosome) technology will help Athersys develop gene therapies. Before founding Athersys in 1995, Gil Van Bokkelen and John Harrington worked on research underlying the SMC technology.

 COMPETITION
Affymetrix, Inc. (AFFX)
CuraGen Corporation (CRGN)
Gene Logic Inc. (GLGC)

 FINANCIAL OVERVIEW
Fiscal Year-End: December
1999 Sales (mil.): 0.00
Employees: 75
Revenue per employee: $0.00

 KEY PEOPLE
• Gil Van Bokkelen
    CEO
• Jeffrey R. Steinhilber
    CFO

 CONTACT INFO
3201 Carnegie Ave.
Cleveland, OH 44115
US
Phone: 216-431-9900
Fax: 216-361-9495
Online: Web Site

Company Data   News, quotes & more       

Hoovers Online   Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.


ADVERTISEMENT
FEATURED LINKS
Home |  Customer Service |  About Us
Australia |  Brazil |  China |  Korea |  Norway |  Poland |  Sweden |  Taiwan

Copyright ©2001 Standard Media International. Privacy Policy
Stock data provided by Stockpoint and its data suppliers. Copyright © 1995-2001